New 52 Week Low Today

Incyte Corp INCY:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 09/24/21 EDT
69.00UNCH (UNCH)
Volume
101,419
Close
69.00quote price arrow down-0.78 (-1.12%)
Volume
1,302,758
52 week range
68.62 - 101.47
Loading...
  • Open69.69
  • Day High70.14
  • Day Low68.62
  • Prev Close69.78
  • 52 Week High101.47
  • 52 Week High Date01/25/21
  • 52 Week Low68.62
  • 52 Week Low Date09/24/21

Key Stats

  • Market Cap15.238B
  • Shares Out220.84M
  • 10 Day Average Volume2.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • YTD % Change-20.67

KEY STATS

  • Open69.69
  • Day High70.14
  • Day Low68.62
  • Prev Close69.78
  • 52 Week High101.47
  • 52 Week High Date01/25/21
  • 52 Week Low68.62
  • 52 Week Low Date09/24/21
  • Market Cap15.238B
  • Shares Out220.84M
  • 10 Day Average Volume2.10M
  • Dividend-
  • Dividend Yield-
  • Beta0.79
  • YTD % Change-20.67

RATIOS/PROFITABILITY

  • EPS (TTM)1.53
  • P/E (TTM)45.16
  • Fwd P/E (NTM)20.18
  • EBITDA (MRQ)532.205M
  • ROE (MRQ)12.79%
  • Revenue (MRQ)2.721B
  • Gross Margin (MRQ)95.72%
  • Net Margin (MRQ)12.41%
  • Debt To Equity (MRQ)1.17%

EVENTS

  • Earnings Date11/03/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia...
Herve Hoppenot
Chairman
Christiana Stamoulis
Chief Financial Officer
Maria Pasquale J.D.
Executive Vice President
Paula Swain
Executive Vice President
Michael Morrissey
Executive Vice President
Address
1801 Augustine Cut off
Wilmington, DE
19803-4404
United States

Top Peers

SYMBOLLASTCHG%CHG
CRL
Charles River Laboratories International Inc
458.30+3.26+0.72%
EXAS
Exact Sciences Corp
96.02-2.20-2.24%
NVZMY
Novozymes A/S
73.17-1.90-2.53%
NVAX
Novavax Inc
248.16-9.14-3.55%
NBIX
Neurocrine Biosciences Inc
94.99-0.06-0.06%